CP
REGN icon

Cumberland Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Cumberland Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Buy
+1,500
New +$1.15M 0.09% 120

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cumberland Partners's REGN Position: Q1 2026 in Review

Cumberland Partners opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 1,500 shares worth $1.16M. The stake represents 0.09% of the portfolio and ranks #120 among its holdings.

1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Cumberland Partners held 1,500 shares of Regeneron Pharmaceuticals worth $1.16M as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Cumberland Partners position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.09% of Cumberland Partners's portfolio in Q1 2026, its #120 holding.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Cumberland Partners's 13F filing for Q1 2026, filed 14 May 2026.